Noteworthy Thursday Option Activity: JNJ, MRNA, ALB

Options activity is unusually heavy in Moderna and Albemarle: MRNA saw 55,785 contracts trade today (≈5.6 million underlying shares), about 45.5% of its one‑month average daily volume (12.3M), led by 6,094 contracts in the $25 call expiring Nov. 28, 2025 (≈609,400 shares). ALB registered 18,359 contracts (≈1.8M underlying shares), about 45.1% of its one‑month average daily volume (4.1M), highlighted by 10,000 contracts in the $60 put expiring Dec. 19, 2025 (≈1.0M shares). Such large option flows—each equating to roughly half a day’s average share turnover—represent meaningful directional or hedging positioning that could affect near‑term liquidity and price dynamics for both stocks.

Analysis

Moderna (MRNA) experienced unusually high options activity with 55,785 contracts traded today, representing roughly 5.6 million underlying shares and about 45.5% of its one-month average daily volume of 12.3 million shares. The most active instrument was the $25 call expiring November 28, 2025, with 6,094 contracts (~609,400 underlying shares) changing hands, indicating concentrated long‑dated call interest in that strike and expiry.

Albemarle (ALB) logged 18,359 option contracts (~1.8 million underlying shares), also about 45.1% of its one‑month average daily volume of 4.1 million shares; activity was dominated by 10,000 contracts in the $60 put expiring December 19, 2025 (~1.0 million shares). The put-heavy concentration suggests sizable bearish hedging or speculative positioning in that December 2025 strike.

These flows are large relative to each stock’s typical liquidity and therefore have the potential to influence near‑term price dynamics and bid/ask spreads; the market‑impact score in the signals is modest (0.3) and per‑ticker sentiment is mildly positive for MRNA and negative for ALB. Given the long-dated expiries, the trades represent directional or hedging convictions through late 2025 rather than short-term intraday scalps, so investors should watch for follow‑through in underlying price action and implied volatility before adjusting exposure.

Key Decisions for Investors

• Monitor underlying price action and implied volatility for MRNA to confirm bullish signals implied by the concentrated $25 Nov‑28‑2025 call flow before adding directional exposure
• Treat the ALB $60 Dec‑19‑2025 put concentration as a signal to assess downside exposure and consider protective hedges or buying puts rather than initiating uncovered short positions